Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell Disease

NCT04432623 is registered in ClinicalTrials.gov with Phoenicia BioScience as lead sponsor.

NCT NCT04432623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04432623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell Disease
Lead sponsor
Phoenicia BioScience
Phase
Phase 1/2
Overall status
Enrolling by invitation
Start date
October 5, 2020
Completion date
February 28, 2026
Enrollment
36 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

beta thalassemia intermedia, sickle cell disease